167 related articles for article (PubMed ID: 33770057)
1. Prognostic and Theranostic Biomarkers in Ovarian Clear Cell Carcinoma.
Wiedemeyer K; Wang L; Kang EY; Liu S; Ou Y; Kelemen LE; Feil L; Anglesio MS; Glaze S; Ghatage P; Nelson GS; Köbel M
Int J Gynecol Pathol; 2022 Mar; 41(2):168-179. PubMed ID: 33770057
[TBL] [Abstract][Full Text] [Related]
2. [Clinical significance of targeting drug-based molecular biomarkers expression in ovarian clear cell carcinoma].
Li MJ; Li HR; Cheng X; Bi R; Tu XY; Liu F; Chen LH
Zhonghua Fu Chan Ke Za Zhi; 2017 Dec; 52(12):835-843. PubMed ID: 29325268
[No Abstract] [Full Text] [Related]
3. Prognostic impact of interleukin-6 expression in stage I ovarian clear cell carcinoma.
Kawabata A; Yanaihara N; Nagata C; Saito M; Noguchi D; Takenaka M; Iida Y; Takano H; Yamada K; Iwamoto M; Kiyokawa T; Okamoto A
Gynecol Oncol; 2017 Sep; 146(3):609-614. PubMed ID: 28673661
[TBL] [Abstract][Full Text] [Related]
4. Analysis of gene expression signatures identifies prognostic and functionally distinct ovarian clear cell carcinoma subtypes.
Tan TZ; Ye J; Yee CV; Lim D; Ngoi NYL; Tan DSP; Huang RY
EBioMedicine; 2019 Dec; 50():203-210. PubMed ID: 31761620
[TBL] [Abstract][Full Text] [Related]
5. Genomic profiling of ovarian clear cell carcinoma in Chinese patients reveals potential prognostic biomarkers for survival.
Ye S; Zhou S; Wu Y; Pei X; Jiang W; Shi W; Yang W; Zhou X; Shan B; Yang H
Ann Med; 2023 Dec; 55(1):2218104. PubMed ID: 37272300
[TBL] [Abstract][Full Text] [Related]
6. Demographic Clinical and Prognostic Factors of Primary Ovarian Adenocarcinomas of Serous and Clear Cell Histology-A Comparative Study.
Schnack TH; Høgdall E; Nedergaard L; Høgdall C
Int J Gynecol Cancer; 2016 Jan; 26(1):82-90. PubMed ID: 26569060
[TBL] [Abstract][Full Text] [Related]
7. DEF6 expression in ovarian carcinoma correlates with poor patient survival.
Liew PL; Fang CY; Lee YC; Lee YC; Chen CL; Chu JS
Diagn Pathol; 2016 Aug; 11(1):68. PubMed ID: 27488395
[TBL] [Abstract][Full Text] [Related]
8. Tissue factor pathway inhibitor‑2 is specifically expressed in ovarian clear cell carcinoma tissues in the nucleus, cytoplasm and extracellular matrix.
Ota Y; Koizume S; Nakamura Y; Yoshihara M; Takahashi T; Sato S; Myoba S; Ohtake N; Kato H; Yokose T; Miyagi E; Miyagi Y
Oncol Rep; 2021 Mar; 45(3):1023-1032. PubMed ID: 33650653
[TBL] [Abstract][Full Text] [Related]
9. Expression and significance of CD44, CD47 and c-met in ovarian clear cell carcinoma.
Wang H; Tan M; Zhang S; Li X; Gao J; Zhang D; Hao Y; Gao S; Liu J; Lin B
Int J Mol Sci; 2015 Feb; 16(2):3391-404. PubMed ID: 25658794
[TBL] [Abstract][Full Text] [Related]
10. Chromosome 20q13.2 ZNF217 locus amplification correlates with decreased E-cadherin expression in ovarian clear cell carcinoma with PI3K-Akt pathway alterations.
Huang HN; Huang WC; Lin CH; Chiang YC; Huang HY; Kuo KT
Hum Pathol; 2014 Nov; 45(11):2318-25. PubMed ID: 25281027
[TBL] [Abstract][Full Text] [Related]
11. IGF2BP3 (IMP3) expression is a marker of unfavorable prognosis in ovarian carcinoma of clear cell subtype.
Köbel M; Xu H; Bourne PA; Spaulding BO; Shih IeM; Mao TL; Soslow RA; Ewanowich CA; Kalloger SE; Mehl E; Lee CH; Huntsman D; Gilks CB
Mod Pathol; 2009 Mar; 22(3):469-75. PubMed ID: 19136932
[TBL] [Abstract][Full Text] [Related]
12. Prognostic value of programmed death-ligand 1 (PD-L1) expression in ovarian clear cell carcinoma.
Zhu J; Wen H; Bi R; Wu Y; Wu X
J Gynecol Oncol; 2017 Nov; 28(6):e77. PubMed ID: 29027395
[TBL] [Abstract][Full Text] [Related]
13. Impact of iASPP on chemoresistance through PLK1 and autophagy in ovarian clear cell carcinoma.
Chan KK; Wong OG; Wong ES; Chan KK; Ip PP; Tse KY; Cheung AN
Int J Cancer; 2018 Sep; 143(6):1456-1469. PubMed ID: 29663364
[TBL] [Abstract][Full Text] [Related]
14. Clinicopathological and survival characteristic of mismatch repair status in ovarian clear cell carcinoma.
Zhu J; Ke G; Bi R; Wu X
J Surg Oncol; 2020 Sep; 122(3):538-546. PubMed ID: 32396667
[TBL] [Abstract][Full Text] [Related]
15. Expression of protease-activated receptor-2 (PAR-2) is related to advanced clinical stage and adverse prognosis in ovarian clear cell carcinoma.
Aman M; Ohishi Y; Imamura H; Shinozaki T; Yasutake N; Kato K; Oda Y
Hum Pathol; 2017 Jun; 64():156-163. PubMed ID: 28438620
[TBL] [Abstract][Full Text] [Related]
16. Targeting FXYD2 by cardiac glycosides potently blocks tumor growth in ovarian clear cell carcinoma.
Hsu IL; Chou CY; Wu YY; Wu JE; Liang CH; Tsai YT; Ke JY; Chen YL; Hsu KF; Hong TM
Oncotarget; 2016 Sep; 7(39):62925-62938. PubMed ID: 26910837
[TBL] [Abstract][Full Text] [Related]
17. A clearer view on ovarian clear cell carcinoma.
De Pauw A; Naert E; Van de Vijver K; Philippe T; Vandecasteele K; Denys H
Acta Clin Belg; 2022 Aug; 77(4):792-804. PubMed ID: 34404331
[TBL] [Abstract][Full Text] [Related]
18. HNF-1β in ovarian carcinomas with serous and clear cell change.
DeLair D; Han G; Irving JA; Leung S; Ewanowich CA; Longacre TA; Gilks CB; Soslow RA
Int J Gynecol Pathol; 2013 Nov; 32(6):541-6. PubMed ID: 24071869
[TBL] [Abstract][Full Text] [Related]
19. Gene amplification and protein overexpression of MET are common events in ovarian clear-cell adenocarcinoma: their roles in tumor progression and prognostication of the patient.
Yamamoto S; Tsuda H; Miyai K; Takano M; Tamai S; Matsubara O
Mod Pathol; 2011 Aug; 24(8):1146-55. PubMed ID: 21478826
[TBL] [Abstract][Full Text] [Related]
20. Clinical Characteristics of Clear Cell Ovarian Cancer: A Retrospective Multicenter Experience of 308 Patients in South Korea.
Lee HY; Hong JH; Byun JH; Kim HJ; Baek SK; Kim JY; Kim KH; Yun J; Kim JA; Park K; Lee HJ; Lee JL; Won YW; Kim IH; Bae WK; Park KH; Sun DS; Lee S; Lee MY; Lee GJ; Hong SH; Jung YH; An HJ
Cancer Res Treat; 2020 Jan; 52(1):277-283. PubMed ID: 31319640
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
